B
Bonno N. Bouma
Researcher at Scripps Research Institute
Publications - 150
Citations - 10250
Bonno N. Bouma is an academic researcher from Scripps Research Institute. The author has contributed to research in topics: Fibrinolysis & Thrombin. The author has an hindex of 55, co-authored 150 publications receiving 9931 citations. Previous affiliations of Bonno N. Bouma include University Medical Center Utrecht & Utrecht University.
Papers
More filters
Journal ArticleDOI
High levels of coagulation factor XI as a risk factor for venous thrombosis.
Joost C. M. Meijers,Winnie L.H. Tekelenburg,Bonno N. Bouma,Rogier M. Bertina,Frits R. Rosendaal +4 more
TL;DR: High levels of factor XI are a risk factor for deep venous thrombosis, with a doubling of the risk at levels that are present in 10 percent of the population.
Journal ArticleDOI
Oral contraceptives and the risk of venous thrombosis
Jan P. Vandenbroucke,Jan Rosing,Kitty W. M. Bloemenkamp,Saskia Middeldorp,Frans M. Helmerhorst,Bonno N. Bouma,Frits R. Rosendaal +6 more
TL;DR: In the early 1960s, shortly after the introduction of oral contraceptives, the first case reports appeared describing venous thrombosis and pulmonary emboli in women using this method of birth control, leading to the development of new oral contraceptives with a lower estrogen content.
Journal ArticleDOI
Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII.
Bonno N. Bouma,John H. Griffin +1 more
TL;DR: Results show that the activation of human Factor XI both by purified activated Factor XII and by the contact activation system in plasma involves limited proteolytic cleavage of Factor XI yielding polypeptide chains of IV, = 50,000 and 33,000 which are held together by disulfide bonds.
Journal ArticleDOI
Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis
TL;DR: Thrombin-mediated factor XI activation can take place in plasma under physiologic conditions in the absence of a dextran sulfate-like cofactor and the presence of factor XI during coagulation results in the formation of additional thrombin within the clot capable of protecting this clot from fibrinolytic attack.
Journal ArticleDOI
Thrombin-Activatable Fibrinolysis Inhibitor Deficiency in Cirrhosis Is Not Associated With Increased Plasma Fibrinolysis
Ton Lisman,Frank W.G. Leebeek,Laurent O. Mosnier,Bonno N. Bouma,Joost C. M. Meijers,Harry L.A. Janssen,H. Karel Nieuwenhuis,Philip G. de Groot +7 more
TL;DR: Despite decreased levels of TAFI and other components of the fibrinolytic system, no evidence of increased plasma fibrinelytic potential in cirrhosis is observed using the plasma-based assay of this study.